| Dr Michael Wollman Sanders I, PHARMD, CGP | |
|
128 Alderbrook Dr, Santa Rosa, CA 95405-4602 | |
| (707) 545-0742 | |
| (707) 545-0742 |
| Full Name | Dr Michael Wollman Sanders I |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacotherapy |
| Location | 128 Alderbrook Dr, Santa Rosa, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023002961 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P1200X | Pharmacist - Pharmacotherapy | RPH 27956 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Wollman Sanders I, PHARMD, CGP 128 Alderbrook Dr, Santa Rosa, CA 95405-4602 Ph: (707) 545-0742 | Dr Michael Wollman Sanders I, PHARMD, CGP 128 Alderbrook Dr, Santa Rosa, CA 95405-4602 Ph: (707) 545-0742 |
News Archive
Sigma-Aldrich and Oxford BioMedica have announced that they received a key order confirming the strength and validity of intellectual property owned by Oxford BioMedica and licensed exclusively in the research field to Sigma-Aldrich.
Nine years ago, scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute detected a subtle shift occurring in the molecular makeup of the most aggressive type of brain tumors, glioblastoma multiforme. With further study, they found that a specific protein called laminin-411 plays a major role in a tumor's ability to build new blood vessels to support its growth and spread. But technology did not exist then to block this protein.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.
For the seventh consecutive year, the Training, Research and Education for Driving Safety (TREDS) program at the University of California, San Diego School of Medicine has been awarded a grant from the California Office of Traffic Safety (OTS) that will help keep our roadways and senior drivers safe through professional training.
› Verified 3 days ago
Mr. Gregory Lee Kappes, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1055 W College Ave, Santa Rosa, CA 95401 Phone: 707-484-7104 | |
Christopher Nhiawa Vang, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3093 Marlow Rd, Santa Rosa, CA 95403 Phone: 707-569-8504 | |
Jie Giok Rahardja, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 707-393-4652 | |
Conor William Bowman, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 818-522-1238 | |
Dr. Justin Colucci, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 707-393-4119 Fax: 866-296-6825 | |
Mr. Mark Allen Guttormsen, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1055 W College Ave, Santa Rosa, CA 95401 Phone: 707-575-1313 Fax: 707-575-0104 |